Newswise Baltimore, MD, November 12, 2020 Robert C. Gallo, MD, the Homer & Martha Gudelsky Distinguished Professor in Medicine at the University of Maryland School of Medicine (UMSOM) and Co-Founder & Director of the UMSOMs Institute of Human Virology (IHV), announced today that a team of leading scientists in human immunology, virology and stem cell biology, led by Lishan Su, PhD joined IHV on October 1 with academic appointments in the UMSOM Department of Pharmacology. As part of the Maryland E-Nnovation Initiative Fund (MEIF) to recruit top research faculty and a donation to IHV from the Charles Gordon Estate, Dr. Su has been named the Charles Gordon Smith Endowed Professor for HIV Research. Dr. Su will also head IHVs Division of Virology, Pathogenesis and Cancer.
The team will include a 12-person Laboratory of Viral Pathogenesis and Immunotherapy with two faculty appointments as well as major public and private sector research funding.
Dr. Gallo made the announcement in conjunction with University of Maryland School of Medicine Dean E. Albert Reece, MD, PhD, MBA and Margaret M. McCarthy PhD, James & Carolyn Frenkil Deans Professor, Chair of the Department of Pharmacology.
Dr. Su is one of the most successful active basic researchers in America, said Dr. Gallo, who is also Co-Founder and Chairman of the International Scientific Leadership Board of the Global Virus Network. His research is groundbreaking, and we are so pleased to have him join IHV and lead our Division of Infectious Agents and Cancer, which under his sound leadership, will flourish.
Dr. McCarthy added:Dr. Sus continuing ground-breaking work in HIV and Hepatitis B will be a huge asset to the Department of Pharmacology. I look forward to working with him on advances that could open the door to new therapeutics.
Dr. Su was a faculty member in the Lineberger Comprehensive Cancer Center and Professor in the Department of Microbiology & Immunology at University of North Carolina-Chapel Hill since 1996. He received his BS degree in Microbiology from Shandong University, his PhD degree in Virology from Harvard University, and did his post-doctoral training in Stem Cell Biology & Immunology at Stanford University. He worked as a senior research scientist at SyStemix/Sandoz (Novartis), focusing on HIV-1 pathogenesis and stem cell-based gene therapy in humanized mice and in patients.
I am excited to continue and expand my research programs at the Institute of Human Virology (IHV), said Dr. Su. I have long been impressed by the Baltimore-DC area's research centers with great basic and clinical research programs. IHV, co-founded and directed by Dr. Robert Gallo, is one of the first research institutes in the U.S. to integrate basic science, population studies and clinical trials to understanding and treating human virus-induced diseases. The Department of Pharmacology, headed by Dr. Margaret McCarthy, in the University of Maryland School of Medicine, has been outstanding in developing novel therapeutics including breast cancer drugs. I look forward to working with my new colleagues at IHV and the Department of Pharmacology, and across the University of Maryland School of Medicine, to expand and translate my research programs to treating human inflammatory diseases including virus infection and cancer.
Dr. Su has extensive research experience in human immunology, virology and stem cell biology. Dr. Su made important contributions to several areas of human immunology and infectious diseases, particularly in studying human immuno-pathology of chronic virus infections. His lab at UNC-Chapel Hill published important findings in identifying novel virological and immunological mechanisms of HIV-1 pathogenesis. Furthermore, his lab established humanized mouse models with both human immune and human liver cells that support HCV or HBV infection, human immune responses and human liver fibrosis. In recent years, Dr. Sus group discovered, and focused on, the pDC-interferon axis in the immuno-pathogenesis and therapy of chronic HIV & HBV infections. The group also started investigation of the pDC-IFN axis in tumor microenvironments and in cancer immune therapy.
Im so pleased to welcome Dr. Su to our faculty. His work advances the mission of the School of Medicine, which is to provide important new knowledge in the area of immunology and chronic disease to discover new approaches for treatments, said Dean Reece, who is also University Executive Vice President for Medical Affairs and the John Z. and Akiko K. Bowers Distinguished Professor. Dr. Sus stellar research capabilities will provide vital opportunities for collaboration across our Institutes and Departments.
About the Institute of Human Virology
Formed in 1996 as a partnership between the State of Maryland, the City of Baltimore, the University System of Maryland and the University of Maryland Medical System, IHV is an institute of the University of Maryland School of Medicine and is home to some of the most globally-recognized and world-renowned experts in all of virology. The IHV combines the disciplines of basic research, epidemiology and clinical research in a concerted effort to speed the discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders - most notably, HIV the virus that causes AIDS. For more information,www.ihv.organd follow us on Twitter @IHVmaryland.
About the University of Maryland School of Medicine
The University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States and continues today as an innovative leader in accelerating innovation and discovery in medicine. The School of Medicine is the founding school of the University of Maryland and is an integral part of the 11-campus University System of Maryland. Located on the University of Marylands Baltimore campus, the School of Medicine works closely with the University of Maryland Medical Center to provide a research-intensive, academic and clinically based education. With 43 academic departments, centers and institutes and a faculty of more than 3,000 physicians and research scientists plus more than $400 million in extramural funding, the School is regarded as one of the leading biomedical research institutions in the U.S. with top-tier faculty and programs in cancer, brain science, surgery and transplantation, trauma and emergency medicine, vaccine development and human genomics, among other centers of excellence. The School is not only concerned with the health of the citizens of Maryland and the nation, but also has a global vision, with research and treatment facilities in more than 30 countries around the world. For more information, visitwww.medschool.umaryland.edu.
Read more here:
Leading Human Immunology and Infectious Disease Experts to Join UM School of Medicines Institute of Human Virology - Newswise
- Overcoming Tendonitis: How Stem Cell Treatments Are Revolutionizing Athlete Rehabilitation - Medical Tourism Magazine - February 21st, 2024
- Unproven Stem Cell Treatments Offer Hope & Risks - Healthline - January 4th, 2023
- Stem Cell or Bone Marrow Transplant Side Effects - American Cancer Society - November 24th, 2022
- Stem cell: $137 million buys more clinical trials, shared labs ... - November 24th, 2022
- Stem Cells Australia | Australian research, stem cell treatments and ... - October 29th, 2022
- What is a Bone Marrow Transplant (Stem Cell Transplant)? - Cancer.Net - October 29th, 2022
- Cameron Mathison Is Undergoing Stem Cell Treatments - October 4th, 2022
- Hiltzik: A judge undermines the FDA on stem cells - Los Angeles Times - October 4th, 2022
- Mesoblast Submits New Information to FDA IND File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD - GlobeNewswire - October 4th, 2022
- 15 Years of Heart - Newswise - October 4th, 2022
- QC Kinetix (The Heights) Helping Patients Heal Better from Joint Pain Through Houston Heights Sports Medicine - Yahoo Finance - October 4th, 2022
- Sources - Minnesota Timberwolves' Karl-Anthony Towns was on bed rest for days due to throat infection - ESPN - October 4th, 2022
- Innovative spaces and an expert team help Childrens Hospital New Orleans set the standard in cancer care - NOLA.com - September 25th, 2022
- Stem Cell Transplantation: What it Is, Process & Procedure - September 16th, 2022
- New stem cell therapy provides long-term brain protection against ALS - Study Finds - September 8th, 2022
- $150 Million Gift Takes Stem Cell Research to New Heights - University of California San Diego - September 8th, 2022
- Seattle biotech company is the first to receive approval to test B cell gene therapy in humans - GeekWire - September 8th, 2022
- Kite's CAR T-cell Therapy Tecartus Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia... - September 8th, 2022
- Could Stem-Cell Based Therapy Treat Type-1 Diabetes? A New Study Demonstrates the Treatments Potential - SciTechDaily - August 30th, 2022
- Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio - GlobeNewswire - August 30th, 2022
- Global Cancer Stem Cells Market Estimated to Reach $1,722.7 Million by 2026 and Grow at 10.3% CAGR in the 2019 to 2026 Timeframe | [180-Pages] Report... - August 22nd, 2022
- Getting a Stem Cell or Bone Marrow Transplant - American Cancer Society - August 14th, 2022
- Stem cell therapy to be used in treatment of long COVID by Panacell Biotech - Labiotech.eu - August 14th, 2022
- Selma Blair 'Stopped Looking in the Mirror' After MS Treatments - TooFab - August 14th, 2022
- ElevateBio Announces the Formation of a New Company With George Daley, M.D., Ph.D., and Boston Childrens Hospital to Develop iPSC-Derived Allogeneic... - August 5th, 2022
- Stem Cells Are Needed To Treat Life-Threatening Diseases - Longevity LIVE - Longevity LIVE - July 19th, 2022
- Stem Cell Hair Transplant: What Is It and When Will It Be Available? - July 11th, 2022
- Stem cell treatments and regulation - a quick guide for consumers - July 11th, 2022
- Tisch Multiple Sclerosis Research Center of New York Study Featured in BioSpace - Business Wire - July 3rd, 2022
- NorthX Biologics expands to Cell Therapy: Partnership with Alder Therapeutics and new manufacturing site on Karolinska campus - GlobeNewswire - June 22nd, 2022
- Japan's five hottest biotech companies in healthcare - Labiotech.eu - June 22nd, 2022
- Sickle cell beta thalassemia: Causes, symptoms, and treatments - Medical News Today - June 22nd, 2022
- Umoja Biopharma Presents Data on its Engineered Induced Pluripotent Stem Cell Platform at the 2022 International Society for Stem Cell Research Annual... - June 22nd, 2022
- Six Things to Know About Stem Cell Treatment - HealthTechZone - May 15th, 2022
- CU Anschutz center for cell-based therapy gets $200 million expansion - The Denver Post - May 15th, 2022
- Differentiation therapy, Hox genes and Abemaciclib Research update 13th May - Brain Tumour Research - May 15th, 2022
- Here's the No. 1 Reason to Buy Vertex Pharmaceuticals Now - The Motley Fool - May 15th, 2022
- To help cope with the world's oldest population, Japan is investing in transplanted iPS stem cells - CBS News - April 19th, 2022
- Stem cell cure for lower back pain is all in the 'hiPS' - Study Finds - April 19th, 2022
- Versant-backed startup launches with plans to broaden cell therapy's reach - BioPharma Dive - April 19th, 2022
- CAR NK-Cell Therapy Is Quickly Growing in Immunotherapy - Targeted Oncology - April 19th, 2022
- Robert Vonderheide Appointed to Second Five-Year Term as Director of the Abramson Cancer Center - U Penn - April 19th, 2022
- Signaling Pathways and Targeted Therapies for Stem Cells in Prostate Cancer - DocWire News - April 19th, 2022
- Is Stem Cell Therapy Right for You? - Health Essentials from Cleveland Clinic - April 6th, 2022
- Cleveland Cord Blood Center and Deverra Therapeutics Announce Agreement - PR Newswire - April 6th, 2022
- Early Treatment Matters More Than Ever in Multiple Myeloma, Kumar Says - AJMC.com Managed Markets Network - April 6th, 2022
- Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives - DocWire News - March 25th, 2022
- A Holistic Review on the Current and Future Status of Biology-Driven and Broad-Spectrum Therapeutic Options for Medulloblastoma - Cureus - March 25th, 2022
- Current Strategies and the Potential of CAR T-Cell Therapy in Relapsed and Refractory MCL - AJMC.com Managed Markets Network - March 25th, 2022
- 'I wouldn't be here': Virginia girl, celebrating 11 years in remission, credits St. Jude with saving her life - News 3 WTKR Norfolk - March 25th, 2022
- This weird mouse with a tuft of human hair could be the future of a stem cell treatment for baldness - Boing Boing - January 20th, 2022
- 5 questions facing gene therapy in 2022 - BioPharma Dive - January 20th, 2022
- How Stem Cell and Bone Marrow Transplants Are Used to ... - January 5th, 2022
- The Stem Cell Transplant Process - UChicago Medicine - January 5th, 2022
- Next Chapters: How Northern California blood recipients are doing years after donors helped save their lives - KCRA Sacramento - January 5th, 2022
- Exclusive: Ronnie Coleman on Recent Weight Gain, Current Strength, and Health Progress - BarBend - January 5th, 2022
- Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent ... - KULR-TV - November 8th, 2021
- Managing superficial pyoderma with light therapy - DVM 360 - October 28th, 2021
- New Treatments and Tips for Dealing With Blood Cancer - Curetoday.com - October 28th, 2021
- Orchard Therapeutics Outlines Comprehensive Presence at the - GlobeNewswire - October 16th, 2021
- Taking aim at the brain, Takeda strikes up cell therapy R&D alliance with Immusoft - MedCity News - October 16th, 2021
- The Impact Of Market Restrictions On The US Stem Cell Biomaterials Market - Med Device Online - October 16th, 2021
- FTC Follows Through On Prioritizing Investigations Into False Advertising In Healthcare Markets - Media, Telecoms, IT, Entertainment - United States -... - October 16th, 2021
- FDA Warns About Stem Cell Therapies | FDA - October 5th, 2021
- Anja Health Disrupts Cord Blood Banking with Heartfelt Founding Story and Ground-Breaking Mission - Digital Journal - October 5th, 2021
- Kite's Tecartus is First CAR T Therapy Approved for Adults with B-Cell ALL - Clinical OMICs News - October 5th, 2021
- Prolymphocytic Leukemia: What Is It and How Is It Treated? - Healthline - August 31st, 2021
- Researchers Gaze into Space to Envision Future of Regenerative Medicine - UPMC & Pitt Health Sciences News Blog - UPMC - August 18th, 2021
- Acute Myeloid Leukemia Treatment: What You Need to Know - Healthline - August 18th, 2021
- Study Calls for COVID-19 Vaccination in Patients With Cancer to Enable Optimal Treatment Delivery During Pandemic - OncLive - August 18th, 2021
- A Third Dose of the COVID-19 Vaccine Recommended for Some Cancer Patients With Weakened Immune Systems - On Cancer - Memorial Sloan Kettering - August 18th, 2021
- Stem cells: What they are and what they do - Mayo Clinic - June 6th, 2021
- Stem Cell Therapy for Knee Pain: What Patients Should Know - June 6th, 2021
- Study clarifies the impact of getting old on hematopoietic stem cells - Microbioz India - December 26th, 2020
- Stem Cell Therapy Shows 2-year Benefit for Progressive MS Patients in Phase 1 Trial - Multiple Sclerosis News Today - December 22nd, 2020
- New Combination Therapy Tested By Children's May Offer Hope For Leukemia Patients - WVXU - December 22nd, 2020
- Physio Logic Brings Cutting-edge Regenerative Treatments for Sport Injuries and Arthritis to New York City - PRNewswire - December 22nd, 2020
- For Patients With HMA-Resistant MDS, What Are Their Options? - AJMC.com Managed Markets Network - December 22nd, 2020
- In COVID-19 Clinical Trials, Experts from Baptist Health's Cancer Institutes Treat Patients With Mild or Severe Symptoms - Baptist Health South... - December 22nd, 2020
- SPONSORED: 12 Charities of Christmas - Anthony Nolan - The Courier - December 22nd, 2020